Manufacturers have told the Centers for Disease Control and Prevention they expect to produce as many as 135 million doses of flu vaccine for the United States market in the 2026-2027 season. Every virus in those doses is different from last year’s. The agency’s season page, last updated September 29, 2026, states that all three virus components of the vaccines were updated, and all of the supply is trivalent.
Two separate claims sit inside that opening, and they come from two separate owners. The strain list is a public-health decision, announced in the first half of this year, made by the World Health Organization and by the Food and Drug Administration’s advisory committee. The dose count is a projection from the companies that make the shots. Treating them as one number from one source blurs who is accountable for what.
The three components WHO and FDA chose
The World Health Organization issued its northern hemisphere recommendation on February 27, 2026. For egg-based vaccines it named an A/Missouri/11/2025 (H1N1)pdm09-like virus, an A/Darwin/1454/2025 (H3N2)-like virus and a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus. Vaccines made in cells or with recombinant technology use the same H1N1 strain but a different H3N2 virus, A/Darwin/1415/2025, and a different B virus, B/Pennsylvania/14/2025.
The FDA’s Vaccines and Related Biological Products Advisory Committee took up the same question on March 12, 2026. Contagion Live reported that the panel approved two separate formulations, one for egg-based vaccines and one for cell-culture, recombinant and nucleic-acid products, each by a 7-0 vote with no abstentions. The agency’s own composition page for the season lists the identical six viruses and adds that the agency anticipates an adequate and diverse supply of approved seasonal vaccines.
Subclade K and the H3N2 swap
The reason behind the H3N2 change is spelled out in WHO’s announcement. In August 2025, according to the organization, a notably different variant of the A(H3N2) virus emerged, classified as J.2.4.1 and widely called subclade K, and it spread rapidly across the globe. It dominated reported cases and brought an earlier-than-usual influenza season to many countries.
CDC’s season page ties the new H3N2 component to that same virus, saying the change addresses the subclade K strain that spread widely during the 2025-2026 season. A vaccine built around a virus that stopped circulating would be a poor match, which is the logic behind replacing the component rather than carrying it over. Influenza A(H3N2) viruses drift quickly, so the component is the one most often revisited, and the 2026-2027 formula goes further by revising the H1N1 and B/Victoria components as well, leaving no virus from the prior formula in the shot.
At the March advisory meeting, CDC’s Dr. Lisa Grohskopf presented surveillance data showing a relative increase in influenza B cases and a decrease in influenza A cases that season. She also showed overall vaccine effectiveness estimates ranging from 14 percent to 48 percent across populations, with protection higher against influenza B than influenza A, as Contagion Live summarized the session.
The 135 million dose ceiling from manufacturers
The supply number is worded carefully on the CDC page: manufacturers project they will produce as many as 135 million doses. It is a ceiling set by the companies, relayed by the agency, and not a count of shots already shipped or administered. Actual deliveries depend on production yields and on lot release testing, and the word “projected” in the agency’s own text signals that the final total could land below the figure. Manufacturers in this market are private companies, so the numbers originate in their production plans rather than in a federal purchase.
The same page gives the composition of that projected supply. About 99 percent of the doses contain no thimerosal preservative, 100 percent are trivalent, meaning three-component vaccines, and 27 percent are non-egg-based products. The non-egg share matters because those vaccines use the cell or recombinant viruses, the ones with the A/Darwin/1415/2025 and B/Pennsylvania/14/2025 components, rather than the egg-adapted pair.
Egg and cell production lines
Strain selection happens months before the season so manufacturers have time to build supply, and the schedule leaves little room to change course once the viruses are chosen. CDC’s description of the vaccine process says egg-based production begins when CDC or other laboratories give private-sector manufacturers candidate vaccine viruses. Those viruses are injected into fertilized eggs, incubated for several days, and the product then moves through quality testing, packaging and FDA release testing.
The March decision, not the September announcement, fixed the formula. WHO also publishes its full recommendation as a technical document.
The remaining unknown is how much of the 135 million ceiling is realized. CDC’s page will carry the manufacturers’ distribution totals as the season progresses, and those cumulative figures, not the projection, will show how many of the updated vaccines reach clinics and pharmacies.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Hurricane Hunter radar shows four warning signs that a tropical cyclone is about to strengthen, a University of Miami study found
- NTSB report details how a family of four died when their plane’s nose suddenly pitched up
- Doctors warn a silent liver disease now affects one in three American adults
- Common allergy, bladder and sleep pills tied to sharply higher dementia odds
